MeSH term | MeSH ID | Detail |
---|---|---|
Fasciitis, Necrotizing | D019115 | 1 associated lipids |
Mediastinal Emphysema | D008478 | 1 associated lipids |
Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Morris-Stiff G et al. | Immunosuppression in renal transplantation. Meta-analysis should not have included one of the studies. | 1999 | BMJ | pmid:10531121 |
Knoll GA and Bell RC | Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. | 1999 | BMJ | pmid:10213717 |
Allen BR and Luger TA | Risk: benefit ratio is important in treating atopic dermatitis. | 2002 | BMJ | pmid:12399360 |
Misra DP et al. | Pulmonary co-infection with Nocardia and Aspergillus in a patient with adult-onset Still's disease receiving steroids and tacrolimus. | 2014 | BMJ Case Rep | pmid:25398925 |
Slocum AMY | A surgeon's nightmare: pyoderma gangrenosum with pathergy effect mimicking necrotising fasciitis. | 2017 | BMJ Case Rep | pmid:29269363 |
Maus EA | The importance of challenging your diagnosis even in straightforward cases. | 2012 | BMJ Case Rep | pmid:22847565 |
Mallon DH et al. | A spontaneous coronary arterial dissection associated with a calcineurin inhibitor. | 2012 | BMJ Case Rep | pmid:22783013 |
Borges-Costa J et al. | Kaposi's sarcoma presenting as violaceous macules on the chest of a kidney transplanted patient. | 2016 | BMJ Case Rep | pmid:26759393 |
Bonanni A et al. | Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. | 2015 | BMJ Case Rep | pmid:26376698 |
Wu G et al. | Tacrolimus-induced encephalopathy and polyneuropathy in a renal transplant recipient. | 2013 | BMJ Case Rep | pmid:24311415 |
Purani JM and Purani HJ | Treatment of geographic tongue with topical tacrolimus. | 2014 | BMJ Case Rep | pmid:25085945 |
Viecelli A et al. | Diagnostic and management dilemma of a pancreas-kidney transplant recipient with aplastic anaemia. | 2014 | BMJ Case Rep | pmid:25257886 |
Kirpalani A et al. | Idiosyncratic drug reactions and membranous glomerulopathy. | 2017 | BMJ Case Rep | pmid:28137906 |
Liu HY et al. | Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis. | 2018 | BMJ Case Rep | pmid:29669765 |
Gupta M et al. | Tacrolimus-induced unilateral ischaemic optic neuropathy in a non-transplant patient. | 2012 | BMJ Case Rep | pmid:22914240 |
Krystel-Whittemore M et al. | Polyomavirus nephropathy of the native kidney in a patient with rheumatoid arthritis and pulmonary fibrosis. | 2015 | BMJ Case Rep | pmid:26318171 |
Boyer NL et al. | Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. | 2013 | BMJ Case Rep | pmid:23396921 |
Undre N and Dickinson J | Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. | 2017 | BMJ Open | pmid:28377389 |
Goldsmith PM et al. | Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol. | 2017 | BMJ Open | pmid:28756385 |
Castillo Lugo JA | Clinical and experimental immunosuppression. | 1995 May-Jun | Bol Asoc Med P R | pmid:8573248 |
Varanasi SS and Datta HK | Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfa1 and osterix in ROS 17/2.8 cells. | 2005 | Bone | pmid:15780950 |
Fukunaga J et al. | Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. | 2004 | Bone | pmid:15003790 |
Darcy A et al. | A novel library screen identifies immunosuppressors that promote osteoblast differentiation. | 2012 | Bone | pmid:22421346 |
Voggenreiter G et al. | Immunosuppression with FK506 has no influence on fracture healing in the rat. | 2005 | Bone | pmid:15963777 |
Igarashi K et al. | Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. | 2004 | Bone | pmid:15207740 |
Velasco-Guardado A et al. | Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD. | 2016 | Bone Marrow Transplant. | pmid:26950379 |
Kharfan-Dabaja MA et al. | Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. | 2017 | Bone Marrow Transplant. | pmid:27819684 |
Cutler C et al. | Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. | 2011 | Bone Marrow Transplant. | pmid:20697368 |
Parody R et al. | GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. | 2016 | Bone Marrow Transplant. | pmid:27295268 |
Hale GA et al. | Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis. | 2000 | Bone Marrow Transplant. | pmid:10723590 |
Rotenstein L et al. | Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation. | 2016 | Bone Marrow Transplant. | pmid:27272445 |
Schmook T et al. | Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. | 2005 | Bone Marrow Transplant. | pmid:15895116 |
Wingard JR et al. | Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. | 1997 | Bone Marrow Transplant. | pmid:9232256 |
Miceli M et al. | Significant interaction of tacrolimus with ritonavir during allogeneic hematopoietic SCT in an HIV-infected patient. | 2012 | Bone Marrow Transplant. | pmid:22120984 |
Yanada M et al. | Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. | 2004 | Bone Marrow Transplant. | pmid:15220958 |
Steg RE et al. | Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. | 1999 | Bone Marrow Transplant. | pmid:10338054 |
Tam PM et al. | Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. | 2010 | Bone Marrow Transplant. | pmid:19802037 |
Misawa A et al. | FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation. | 2000 | Bone Marrow Transplant. | pmid:10673708 |
Przepiorka D et al. | Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. | 1999 | Bone Marrow Transplant. | pmid:10414918 |
Okano A et al. | Subcutaneous infection with Mycobacterium fortuitum after allogeneic bone marrow transplantation. | 2001 | Bone Marrow Transplant. | pmid:11704796 |
Parody R et al. | GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. | 2015 | Bone Marrow Transplant. | pmid:25310306 |
Kanda Y et al. | A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. | 2016 | Bone Marrow Transplant. | pmid:26437063 |
Takahata M et al. | Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. | 2001 | Bone Marrow Transplant. | pmid:11704797 |
Espino G et al. | Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. | 2001 | Bone Marrow Transplant. | pmid:11803349 |
Watanabe N et al. | Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children. | 2010 | Bone Marrow Transplant. | pmid:19915626 |
Uberti JP et al. | Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. | 1997 | Bone Marrow Transplant. | pmid:9208118 |
Ohashi Y et al. | Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. | 1997 | Bone Marrow Transplant. | pmid:9085743 |
Ratanatharathorn V et al. | Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. | 2015 | Bone Marrow Transplant. | pmid:25285804 |
Kato H et al. | Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome. | 2014 | Bone Marrow Transplant. | pmid:24317130 |
Mehta P et al. | Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. | 1999 | Bone Marrow Transplant. | pmid:10627642 |
Oshima K et al. | Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT. | 2010 | Bone Marrow Transplant. | pmid:19701249 |
Furlong T et al. | Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. | 2000 | Bone Marrow Transplant. | pmid:11100278 |
Narimatsu H et al. | Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. | 2007 | Bone Marrow Transplant. | pmid:17115066 |
Lekakis L et al. | Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. | 2006 | Bone Marrow Transplant. | pmid:16892072 |
Ikegame K et al. | Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. | 2003 | Bone Marrow Transplant. | pmid:12796797 |
Przepiorka D et al. | Tacrolimus clearance is age-dependent within the pediatric population. | 2000 | Bone Marrow Transplant. | pmid:11041564 |
Ganetsky A et al. | Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. | 2016 | Bone Marrow Transplant. | pmid:26691423 |
Woo M et al. | Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. | 1997 | Bone Marrow Transplant. | pmid:9466284 |
Jabbour E et al. | Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. | 2007 | Bone Marrow Transplant. | pmid:17603511 |
Honda A et al. | Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT. | 2013 | Bone Marrow Transplant. | pmid:22751000 |
Neuman DL et al. | Toxic absorption of tacrolimus [corrected] in a patient with severe acute graft-versus-host disease. | 2005 | Bone Marrow Transplant. | pmid:16151424 |
Khimani F et al. | Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. | 2017 | Bone Marrow Transplant. | pmid:28368376 |
Fuji S et al. | Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT. | 2010 | Bone Marrow Transplant. | pmid:19648969 |
Onizuka M et al. | Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. | 2011 | Bone Marrow Transplant. | pmid:21102498 |
Skeens M et al. | Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. | 2012 | Bone Marrow Transplant. | pmid:22484323 |
Hiraoka A et al. | Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. | 2001 | Bone Marrow Transplant. | pmid:11509936 |
Yu C et al. | Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation. | 1997 | Bone Marrow Transplant. | pmid:9244417 |
Fujino M et al. | Intestinal thrombotic microangiopathy induced by FK506 in rats. | 2007 | Bone Marrow Transplant. | pmid:17277791 |
Kakihana K et al. | Clinical features of calcineurin inhibitor-induced pain syndrome after allo-SCT. | 2012 | Bone Marrow Transplant. | pmid:21625227 |
Yoshida Y et al. | FK506-associated limbic injury following umbilical cord blood transplantation. | 2003 | Bone Marrow Transplant. | pmid:12942100 |
Gaziev D et al. | Chronic graft-versus-host disease: is there an alternative to the conventional treatment? | 2000 | Bone Marrow Transplant. | pmid:10745252 |
Mori T et al. | Drug interaction between voriconazole and tacrolimus in allogeneic hematopoietic SCT recipients. | 2011 | Bone Marrow Transplant. | pmid:20453893 |
Kanamaru A et al. | FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. | 1995 | Bone Marrow Transplant. | pmid:7581086 |
Koehler MT et al. | FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. | 1995 | Bone Marrow Transplant. | pmid:7581088 |
Riley L et al. | Cross-sensitivity reaction between tacrolimus and macrolide antibiotics. | 2000 | Bone Marrow Transplant. | pmid:10808214 |
Jacobson P et al. | Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. | 1998 | Bone Marrow Transplant. | pmid:9720734 |
Hsiao CC et al. | Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD. | 2002 | Bone Marrow Transplant. | pmid:12476284 |
Najera JE et al. | Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis. | 2013 | Bone Marrow Transplant. | pmid:22705799 |
Devine SM et al. | Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. | 1996 | Bone Marrow Transplant. | pmid:8879619 |
Yumura-Yagi K et al. | Unrelated donor bone marrow transplantation for 100 pediatric patients: a single institute's experience. | 2005 | Bone Marrow Transplant. | pmid:15968285 |
Przepiorka D et al. | Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. | 1999 | Bone Marrow Transplant. | pmid:10516680 |
Gondo H et al. | Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. | 2000 | Bone Marrow Transplant. | pmid:11149744 |
Couriel DR et al. | Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. | 2002 | Bone Marrow Transplant. | pmid:12379897 |
Yu C et al. | Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. | 1996 | Bone Marrow Transplant. | pmid:8722370 |
Mori T et al. | Cold agglutinin disease associated with adenovirus infection after allogeneic bone marrow transplantation. | 2005 | Bone Marrow Transplant. | pmid:15937504 |
Uberti JP et al. | Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. | 2004 | Bone Marrow Transplant. | pmid:15273705 |
Sastry J et al. | Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. | 2004 | Bone Marrow Transplant. | pmid:14743193 |
Han CW et al. | Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. | 1995 | Bone Marrow Transplant. | pmid:7545487 |
Castagna L et al. | Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. | 2016 | Bone Marrow Transplant. | pmid:26595078 |
Mookerjee B et al. | Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. | 1999 | Bone Marrow Transplant. | pmid:10482936 |
Prot-Labarthe S et al. | Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. | 2007 | Bone Marrow Transplant. | pmid:17549052 |
Yanagisawa R et al. | Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. | 2011 | Bone Marrow Transplant. | pmid:20383212 |
Shayani S et al. | Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. | 2012 | Bone Marrow Transplant. | pmid:21383680 |
Zohren F et al. | Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. | 2011 | Bone Marrow Transplant. | pmid:20661230 |
Dvorak CC et al. | Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. | 2006 | Bone Marrow Transplant. | pmid:16785867 |
Trede NS et al. | Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. | 1997 | Bone Marrow Transplant. | pmid:9257897 |
Khaled SK et al. | A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. | 2013 | Bone Marrow Transplant. | pmid:23000644 |
Esquirol A et al. | Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. | 2017 | Bone Marrow Transplant. | pmid:28604667 |
Cooper MH et al. | Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. | 1994 | Bone Marrow Transplant. | pmid:7527689 |
Al-Kadhimi Z et al. | Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. | 2017 | Bone Marrow Transplant. | pmid:28581472 |